{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Dai WF"],"funding":["Canadian Institutes of Health Research","CIHR"],"pagination":["2046-2063"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8947246"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["29(3)"],"pubmed_abstract":["Canadian provinces routinely collect patient-level data for administrative purposes. These real-world data (RWD) can be used to generate real-world evidence (RWE) to inform clinical care and healthcare policy. The CanREValue Collaboration is developing a framework for the use of RWE in cancer drug funding decisions. A Data Working Group (WG) was established to identify data assets across Canada for generating RWE of oncology drugs. The mapping exercise was conducted using an iterative scan with informant surveys and teleconference. Data experts from ten provinces convened for a total of three teleconferences and two in-person meetings from March 2018 to September 2019. Following each meeting, surveys were developed and shared with the data experts which focused on identifying databases and"],"journal":["Current oncology (Toronto, Ont.)"],"pubmed_title":["Mapping Canadian Data Assets to Generate Real-World Evidence: Lessons Learned from Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration's RWE Data Working Group."],"pmcid":["PMC8947246"],"funding_grant_id":["154126"],"pubmed_authors":["Peacock S","Denburg A","On Behalf Of The CanREValue Collaboration","McDonald JT","Parmar A","Pataky RE","Turner D","Aurangzeb Z","Cheung W","Dai WF","Chan KKW","Beca JM","Takhar P","Mercer RE","Munoz C","Strumpf E","Somayaji C","Folkins C","Tran D","Alvi R","de Oliveira C","Blommaert S","Dowden J","Tadrous M","Kendell C","McClure C","Urquhart R"],"additional_accession":[]},"is_claimable":false,"name":"Mapping Canadian Data Assets to Generate Real-World Evidence: Lessons Learned from Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration's RWE Data Working Group.","description":"Canadian provinces routinely collect patient-level data for administrative purposes. These real-world data (RWD) can be used to generate real-world evidence (RWE) to inform clinical care and healthcare policy. The CanREValue Collaboration is developing a framework for the use of RWE in cancer drug funding decisions. A Data Working Group (WG) was established to identify data assets across Canada for generating RWE of oncology drugs. The mapping exercise was conducted using an iterative scan with informant surveys and teleconference. Data experts from ten provinces convened for a total of three teleconferences and two in-person meetings from March 2018 to September 2019. Following each meeting, surveys were developed and shared with the data experts which focused on identifying databases and","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Mar","modification":"2025-04-04T23:34:17.609Z","creation":"2025-04-04T23:34:17.609Z"},"accession":"S-EPMC8947246","cross_references":{"pubmed":["35323365"],"doi":["10.3390/curroncol29030165"]}}